clinical trial · NCT00830414
Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women
Teva Pharmaceuticals USA·phase1·completed·n = 124
Healthymedroxyprogesterone acetatemedroxyprogesterone acetate
brief summary
This study compared the rates and extents of medroxyprogesterone absorption from two medroxyprogesterone acetate injection formulations following single 150 mg intramuscular (IM) injections to healthy postmenopausal women.
started
Apr 1, 2002
primary completion
Sep 1, 2002
completion
Sep 1, 2002
last updated
Aug 19, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Pivotal Study to Evaluate the Bioequivalence of 150 mg/1 mL Medroxyprogesterone Acetate Injection in Postmenopausal Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol